BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...
KED Global19h
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...
EMBO Press18h
miR-708-5p is elevated in bipolar patients and can induce mood disorder-associated behavior in mice
R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.
Contract Pharma15h
Fill-Finish Contract Manufacturing for Biologics and Vaccines
BioPlan Associates presents research and projections on the pharma sterile fill-finish industry’s future over the next 10 ...